Abstract:BACKGROUND AND OBJECTIVE:At present, although appropriate radiotherapy and combined treatments are widely used for the patients with primary nasopharyngeal carcinoma (NPC), local or regional recurrence rates are still high. According to clinical performance, pathology, and diagnostic imaging of the patients with the first recurrence of NPC, this study analyzed the clinical features of recurrent NPC to provide a reference for tracking the rules of recurrence after the treatment of patients with NPC.METHODS:Clinical data of 337 patients diagnosed with recurrent NPC for the first time were collected. The diagnoses were based on pathology and/or imaging and the patients were treated at the Sun Yat-sen University Cancer Center between January 1999 and December 2004. Data used for statistical analysis included clinical performance during the patient visit, the extension of the invasion as shown on imaging, pathologic features, Epstein-Barr virus (EBV) serology, restaging, etc.RESULTS:Patients were staged according to the system developed by the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) in 2002. Patients with diseases at stages I/II accounted for 25.2%, while those with stage III/IV accounted for 74.8%. The median interval of relapse was 25 months. Patients had local recurrence (69.4%), regional recurrence (4.5%), or both (26.1%). Epistaxis and headache were the most common symptoms. Abduct dysfunction and facial numbness induced by cranial nerve damage were the most common signs. The probability of invasion of structures adjacent to the nasopharynx, such as the oropharynx, the prestyloid space, and the carotid sheath area, was low in patients with recurrent NPC. By contrast, the probability of invasion of structures far from the nasopharynx, such as the base of the skull, the paranasal sinuses, cranial nerves, the cavernous sinus, the brain, the pterygopalatine fossa, the infratemporal fossa, the orbital apex, and the soft palate, was higher in recurrent NPC.CONCLUSIONS:The most common interval of relapse is about 2 years. The relapsed disease is usually more widespread and located deeper. Most recurrent NPC is advanced disease.

Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma And Challenge

Clinical Analysis of Nasal and Laryngeal Neuroendocrine Carcinoma

Management of recurrent nasopharyngeal carcinoma: current perspectives

Comprehensive Treatment of Recurrent and Metastatic Nasopharyngeal Carcinoma: Advances and Future Directions

[Advance in Diagnosis and Management of Local Recurrent Nasopharyngeal Carcinoma].

Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options

Advance in the clinical research on local recurrent nasopharyngeal carcinoma

Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?

Advances of Radiotherapy Combined with Targeted Therapy for Nasopharyngeal Carcinoma

Clinical Features of 337 Patients with Recurrent Nasopharyngeal Carcinoma

Research Progress in Local Therapy of Recurrent Nasopharyngeal Carcinoma

Emerging Treatment Options for Nasopharyngeal Carcinoma

A combined microinvasive trans-submandibular and nasendoscopy surgical approach to dissect recurrent or radiotherapy-insensitive nasopharyngeal carcinoma

[Endonasal Endoscopic Salvage Surgical Treatment for Local Recurrent Nasopharyngeal Cancer].

Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma

[New developments in the management of nasopharyngeal carcinoma]

Clinical Trials in Nasopharyngeal Carcinoma—past, Present and Future

[Efficacy of endoscopic surgical management for recurrent nasopharyngeal carcinoma]

Clinical Advances in Nasopharyngeal Carcinoma Surgery and a Video Demonstration

Enhanced MRI Radiomics Based Model for Predicting Recurrence or Metastasis of Nasopharyngeal Cancer (NC) Undergoing Concurrent Chemoradiotherapy: A Retrospective Study

Clinical characteristics of recurrent nasopharyngeal carcinoma in high-incidence area.